Treatment of HIV-Associated Burkitt Lymphoma - European Medical Journal

Treatment of HIV-Associated Burkitt Lymphoma

Hematology
Download PDF
Authors:
Giovanni Donadoni,1,2 Marta Bruno-Ventre,1,3 Andrés J. M. Ferreri1,2
Disclosure:

No potential conflict of interest.

Citation
EMJ Hematol. ;1[1]:38-52.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

Abstract

Burkitt lymphoma (BL) is a highly aggressive B-cell malignancy, occurring with increased frequency among patients infected with HIV. For several years, the immunocompromised state of HIV-positive patients was advocated as a sufficient reason to avoid the intensive chemotherapeutic regimens used in HIV-negative BL. However, with the introduction of the highly active antiretroviral therapy (HAART), the subsequent improvement of the immunological state of HIV-positive patients, and the disappointing results of less intensive schedules, investigators began to apply the same chemotherapeutic regimens used as a gold standard in HIV-negative non-Hodgkin lymphoma (NHL), including the use of rituximab. Despite promising results of different schedules in early-phase studies, agreement on the treatment of HIV-positive BL is still lacking, and further trials are needed to define a standard of care. Moreover, new treatment frontiers need to focus on improving the outcome for patients with advanced immunosuppression, unfavourable prognostic features- such as advanced stages and high International Prognostic Index (IPI) scores – and for those with adverse tumour biology.

This paper aims to revise the main epidemiological and physiopathological features of HIV-positive BL, to summarise the most relevant steps in the treatment of affected patients, and to elucidate the role of HAART in allowing HIV-positive patients to be managed with the therapeutic strategies currently used in HIV-negative patients with BL.

Please view the full content in the pdf above.

Join our mailing list

To receive the EMJ updates straight to your inbox free of charge, please click the button below.
Join Now